AI at the Bottleneck: The FDA's Blueprint for Smarter Early-Phase Trials

Podcast: AI in Medicine - curated summaries making complex issues easy to understand · Mike Rawson

Opublikowano: 2026-10-19

The FDA is seeking input on a new pilot program exploring how artificial intelligence can optimize early-phase clinical trials. Maya and Sam unpack the agency's goals—from accelerating dose selection to guiding critical go/no-go decisions—and what these proposed standards mean for pharma sponsors and AI developers. Key points The FDA identifies early-phase clinical trials as a critical bottleneck characterized by high uncertainty and inefficient decision-making processes.The proposed pilot program aims to explore how AI can improve trial efficiency, enhance safety monitoring, and support earlier Phase 1 to Phase 2 decisions.The FDA emphasizes that AI use...